Format

Send to

Choose Destination
See comment in PubMed Commons below
Br J Ophthalmol. 2014 Aug;98(8):1003-8. doi: 10.1136/bjophthalmol-2013-304687. Epub 2014 Feb 10.

Reporting of harms by randomised controlled trials in ophthalmology.

Author information

  • 1Clinical Ophthalmology & Eye Health, The University of Sydney, Sydney, Australia.
  • 2Westmead Hospital, Sydney, Australia.
  • 3Clinical Ophthalmology & Eye Health, The University of Sydney, Sydney, Australia Department of Ophthalmology, University Hospital Zurich, The University of Zurich, Switzerland, Switzerland.

Abstract

To evaluate the reporting of harms by randomised controlled trials investigating intravitreal therapies for diabetic macular oedema. A thorough literature search identified eligible reports. Two authors independently extracted data from these articles using a prospectively created checklist. The main outcome measure was compliance with the 10 recommendations of the 2004 Consolidated Standards of Reporting Trials statement extension for better harms reporting. Secondary outcomes were the predictors of the number of recommendations met and the amount of space devoted to harms reporting. Thirty-six reports involving 7246 eyes met the criteria for analysis. The fidelity of the data extraction was excellent, with Cohen's κ coefficient of 0.90 for all items extracted. The median number of recommendations met was six, IQR 5-7. Recommendation 4 (describe how harms-related information was collected) was met by 97% of articles and recommendation 8 (present the absolute risk of each adverse event) by 92%. The least frequently met recommendations were numbers 3 (list addressed adverse events with definitions of each), 31%, and 6 (describe participant withdrawals because of harms), 36%. The mean percentage of the results section devoted to harms-related data was 25.8%, SD 10.8%. Harms reporting in published reports of trials of intravitreal therapies for diabetic macular oedema is still not entirely adequate despite increased attention and efforts to standardise it.

KEYWORDS:

Clinical Trial; Macula; Retina

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center